AR124712A1 - Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos - Google Patents
Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismosInfo
- Publication number
- AR124712A1 AR124712A1 ARP220100165A ARP220100165A AR124712A1 AR 124712 A1 AR124712 A1 AR 124712A1 AR P220100165 A ARP220100165 A AR P220100165A AR P220100165 A ARP220100165 A AR P220100165A AR 124712 A1 AR124712 A1 AR 124712A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- species
- antibody
- heavy chain
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención proporciona composiciones de anticuerpos anti-PD-1 o fragmentos de unión a antígeno de los mismos con menos de, o igual a, aproximadamente un 3,0% de oxidación de Met105 en la región de cadena pesada de CDRH3, y métodos para obtener las composiciones purificadas. La invención también proporciona composiciones que comprenden especies principales de anticuerpos anti-PD-1 y especies ácidas de los mismos, en donde la cantidad de especies ácidas es de aproximadamente 1,0 - 12,0%. Reivindicación 1: Una composición que comprende un anticuerpo anti-PD-1 humano o un fragmento de unión al antígeno del mismo, en donde el anticuerpo anti-PD-1 humano o el fragmento de unión a antígeno del mismo comprende una región variable de cadena ligera que comprende tres CDR de cadena ligera que comprenden CDRL1 de SEQ ID Nº 1, CDRL2 de SEQ ID Nº 2 y CDRL3 de SEQ ID Nº 3 y una región variable de cadena pesada que comprende tres CDR de cadena pesada de CDRH1 de SEQ ID Nº 6, CDRH2 de SEQ ID Nº 7 y CDRH3 de SEQ ID Nº 8, en donde dicho anticuerpo o fragmento de unión a antígeno del mismo, tiene menos de, o igual a, aproximadamente un 3,0% de oxidación de Metionina 105. Reivindicación 12: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano producido a partir de una célula de ovario chino que comprende un polinucleótido que codifica una cadena ligera y un polinucleótido que codifica una cadena pesada, o un polinucleótido que codifica una cadena ligera y una cadena pesada, en donde la cadena pesada consiste en la secuencia de aminoácidos de SEQ ID Nº 10, 13 ó 15, y la cadena ligera consiste en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas de las especies principales del anticuerpo anti-PD-1 humano, en donde la cantidad de especies ácidas es de 1,0 - 12,0%. Reivindicación 13: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano que comprende un anticuerpo que consiste en dos cadenas pesadas y dos cadenas ligeras, consistiendo cada cadena pesada en la secuencia de aminoácidos de SEQ ID Nº 11, y consistiendo cada cadena ligera en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas y básicas de la especie principal del anticuerpo anti-PD-1 humano, en donde la cantidad de especies principales es de 65 - 85%.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163143461P | 2021-01-29 | 2021-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124712A1 true AR124712A1 (es) | 2023-04-26 |
Family
ID=80786902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100165A AR124712A1 (es) | 2021-01-29 | 2022-01-27 | Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220251205A1 (es) |
EP (1) | EP4284834A1 (es) |
JP (1) | JP2024505524A (es) |
CN (1) | CN117043194A (es) |
AR (1) | AR124712A1 (es) |
AU (1) | AU2022212007A1 (es) |
CA (1) | CA3206669A1 (es) |
TW (1) | TW202237657A (es) |
WO (1) | WO2022165001A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024165043A1 (en) * | 2023-02-08 | 2024-08-15 | Beigene Switzerland Gmbh | Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff) |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
WO2008052101A2 (en) | 2006-10-25 | 2008-05-02 | President And Fellows Of Harvard College | Multiplex automated genome engineering |
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
WO2012018538A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Bioassays for determining pd-1 modulation |
MX355624B (es) | 2011-12-22 | 2018-04-25 | Hoffmann La Roche | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2015016786A1 (en) | 2013-08-02 | 2015-02-05 | Agency For Science, Technology And Research | Mutated internal ribosomal entry site (ires) for controlled gene expression |
EP3030659A4 (en) | 2013-08-05 | 2017-01-11 | Tocagen Inc. | Recombinant vector with optimized a-bulge |
ES2681622T3 (es) | 2013-09-18 | 2018-09-14 | Kymab Limited | Métodos, células y organismos |
JP6174811B2 (ja) | 2013-12-11 | 2017-08-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ゲノムの標的改変のための方法及び組成物 |
WO2015157579A2 (en) | 2014-04-09 | 2015-10-15 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
US10344285B2 (en) | 2014-04-09 | 2019-07-09 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
WO2016003368A1 (en) | 2014-07-01 | 2016-01-07 | Agency For Science, Technology And Research | Optimized vectors for the production of recombinant proteins |
CA2967060A1 (en) | 2014-11-10 | 2016-05-19 | Murdoch Childrens Research Institute | Vectors and methods for targeted integration in loci comprising constitutively expressed genes |
US20170204446A1 (en) * | 2016-01-15 | 2017-07-20 | Artemis BioSystems Inc. | System for rapid continuous manufacturing of monoclonal antibodies |
US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618866A4 (en) | 2017-05-02 | 2021-07-14 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHOD OF USING THEREOF |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
SG11202004273YA (en) * | 2017-12-11 | 2020-06-29 | Amgen Inc | Continuous manufacturing process for bispecific antibody products |
US20220033845A1 (en) | 2018-09-24 | 2022-02-03 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
WO2020168315A1 (en) | 2019-02-15 | 2020-08-20 | Just-Evotec Biologics, Inc. | Automated biomanufacturing systems, facilities, and processes |
MX2021014644A (es) * | 2019-06-13 | 2022-04-06 | Amgen Inc | Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos. |
-
2022
- 2022-01-27 JP JP2023545829A patent/JP2024505524A/ja active Pending
- 2022-01-27 US US17/586,109 patent/US20220251205A1/en active Pending
- 2022-01-27 AR ARP220100165A patent/AR124712A1/es unknown
- 2022-01-27 CA CA3206669A patent/CA3206669A1/en active Pending
- 2022-01-27 EP EP22704657.0A patent/EP4284834A1/en active Pending
- 2022-01-27 CN CN202280022248.0A patent/CN117043194A/zh active Pending
- 2022-01-27 WO PCT/US2022/014055 patent/WO2022165001A1/en active Application Filing
- 2022-01-27 AU AU2022212007A patent/AU2022212007A1/en active Pending
- 2022-01-27 TW TW111103668A patent/TW202237657A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20220251205A1 (en) | 2022-08-11 |
CN117043194A (zh) | 2023-11-10 |
TW202237657A (zh) | 2022-10-01 |
JP2024505524A (ja) | 2024-02-06 |
WO2022165001A1 (en) | 2022-08-04 |
EP4284834A1 (en) | 2023-12-06 |
CA3206669A1 (en) | 2022-08-04 |
AU2022212007A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
HRP20170444T1 (hr) | Projektirana anti-il-23 antitijela | |
PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
HRP20240182T1 (hr) | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
NZ610153A (en) | Novel anti-dr5 antibody | |
AR123480A1 (es) | Moléculas de unión terapéuticas | |
RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
AR082194A1 (es) | Anticuerpos anti-ron |